<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharmaceutical Product Guide &#187; NDA</title>
	<atom:link href="http://www.pharmaceuticalproductguide.com/blog/tag/nda/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.pharmaceuticalproductguide.com/blog</link>
	<description>A comprehensive guide to pharmaceutical products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 09:15:33 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>ZENPEP approved by FDA for EPI</title>
		<link>http://www.pharmaceuticalproductguide.com/blog/2009/08/28/zenpep-approved-by-fda-for-epi/</link>
		<comments>http://www.pharmaceuticalproductguide.com/blog/2009/08/28/zenpep-approved-by-fda-for-epi/#comments</comments>
		<pubDate>Fri, 28 Aug 2009 15:27:08 +0000</pubDate>
		<dc:creator>Kimberly O'Brien</dc:creator>
				<category><![CDATA[FDA Approval]]></category>
		<category><![CDATA[cystic fibrosis]]></category>
		<category><![CDATA[EPI]]></category>
		<category><![CDATA[Eurand]]></category>
		<category><![CDATA[exocrine pancreatic insufficiency]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[NDA]]></category>
		<category><![CDATA[new drug application]]></category>
		<category><![CDATA[pancreatic enzyme product]]></category>
		<category><![CDATA[pancrelipase]]></category>
		<category><![CDATA[PEP]]></category>
		<category><![CDATA[ZENPEP]]></category>

		<guid isPermaLink="false">http://www.pharmaceuticalproductguide.com/blog/?p=113</guid>
		<description><![CDATA[Eurand NV has received approval from the FDA for its New Drug Application (NDA) for ZENPEP (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) or other conditions. ZENPEP is the only FDA-approved pancreatic enzyme product (PEP) that has been evaluated in clinical studies in adults and [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.pharmaceuticalproductguide.com/blog/wp-content/uploads/2009/08/Eurand.png"><img class="alignright size-full wp-image-114" style="margin: 5px" src="http://www.pharmaceuticalproductguide.com/blog/wp-content/uploads/2009/08/Eurand.png" alt="Eurand" width="200" height="62" /></a>Eurand NV has received approval from the FDA for its New Drug Application (NDA) for ZENPEP (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) or other conditions. ZENPEP is the only FDA-approved pancreatic enzyme product (PEP) that has been evaluated in clinical studies in adults and children aged one to 12 years. The drug will be available in four dosage strengths to meet the varied needs of infants, toddlers, adolescents and adults with EPI.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.pharmaceuticalproductguide.com/blog/2009/08/28/zenpep-approved-by-fda-for-epi/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mylan receives approval for generic Cytomel</title>
		<link>http://www.pharmaceuticalproductguide.com/blog/2009/07/17/mylan-receives-approval-for-generic-cytomel/</link>
		<comments>http://www.pharmaceuticalproductguide.com/blog/2009/07/17/mylan-receives-approval-for-generic-cytomel/#comments</comments>
		<pubDate>Fri, 17 Jul 2009 18:30:23 +0000</pubDate>
		<dc:creator>Kimberly O'Brien</dc:creator>
				<category><![CDATA[FDA Approval]]></category>
		<category><![CDATA[Cytomel]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[liothyronine sodium]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[NDA]]></category>
		<category><![CDATA[new drug application]]></category>
		<category><![CDATA[thyroid deficiency]]></category>

		<guid isPermaLink="false">http://www.pharmaceuticalproductguide.com/blog/2009/07/17/mylan-receives-approval-for-generic-cytomel/</guid>
		<description><![CDATA[Mylan Pharmaceuticals has received approval from the FDA for its abbreviated new drug application (NDA) for liothyronine sodium tablets USP. The drug will be available in the strengths of 5mcg, 25mcg and 50mcg. Liothyronine sodium tablets are the generic version of King Pharmaceuticals&#8217;s treatment for thyroid deficiency, Cytomel. The company has started the shipping of [...]]]></description>
			<content:encoded><![CDATA[<p><img src="http://www.pharmaceuticalproductguide.com/blog/wp-content/uploads/2009/07/mylan.png" align="left" height="54" width="200" vspace="5" hspace="5" />Mylan Pharmaceuticals has received approval from the FDA for its abbreviated new drug application (NDA) for liothyronine sodium tablets USP. The drug will be available in the strengths of 5mcg, 25mcg and 50mcg. Liothyronine sodium tablets are the generic version of King Pharmaceuticals&#8217;s treatment for thyroid deficiency, Cytomel. The company has started the shipping of the product.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.pharmaceuticalproductguide.com/blog/2009/07/17/mylan-receives-approval-for-generic-cytomel/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
